Development and validation of a Health Policy Model of Type 2 diabetes in Chinese setting
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Due to the difference in epidemiology and outcomes between eastern and western populations with Type 2 diabetes mellitus (T2DM), an important challenge is determining how useful the outcomes from diabetes models based on western populations are for eastern patients. Consequently, the principal aim of this study was to develop and validate a Health Policy Model (Chinese Outcomes Model for T2DM [COMT]) for supporting Chinese medical and health economic studies. Methods: The model is created to simulate a series of important complications of T2DM diabetes based on the latest Risk Equations for Complications of Type 2 Diabetes, which was adjusted by adding the adjustment regulator to the linear predictor within the risk equation. The validity of the model was conducted by using a total of 171 validation outcomes from seven studies in eastern populations and ten studies in western populations. The simulation cohorts in the COMT model were generated by copying each validation study’s baseline characteristics. Concordance was tested by assessing the difference between the identity (45°) line and the best-fitting regression of the scatterplots for the predicted versus observed outcomes. Results: The slope coefficients of the best-fitting regression line between the predicted and corresponding observed actual outcomes was 0.9631 and the R2 was 0.8701. There were major differences between western and eastern populations. The slope and R2 of predictions were 0.9473 and 0.9272 in the eastern population and 1.0566 and 0.8863 in the western population, which showed more perfect agreement with the observed values in the eastern population than the western populations. The subset of macro-vascular and micro-vascular outcomes in the eastern population showed an identical tendency (the slope coefficient was close to 1), and mortality outcomes showed a slight tendency toward overestimation (the slope coefficient was close to 0.9208). Some degree of underprediction of macro-vascular and micro-vascular end points and overprediction of mortality end point was found in the western population. Conclusion: The COMT diabetes model simulated the long-term patient outcomes observed in eastern Asian T2DM patients with prediction accuracy. This study supports the COMT as a credible tool for Chinese healthcare decision makers. Further work is necessary to incorporate new local data to improve model validity and credibility.
Supplementary Material
File (suppl_table_1.pdf)
- Download
- 48.90 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
GBD 2016 DALYs, HALE Collaborators. Global, regional and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100), 1260–1344 (2017).
2.
Wang L, Gao P, Zhang M et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317(24), 2515–2523 (2017).
3.
Xu Y, Wang L, He J et al. Prevalence and control of diabetes in Chinese adults. JAMA 310(9), 948–959 (2013).
4.
Chan JC, Zhang Y, Ning G. Diabetes in China: a societal solution for a personal challenge. Lancet Diabetes Endocrinol. 2(12), 969–979 (2014).
5.
Wang H, Lin X, Zhang Z et al. The economic burden of inpatients with Type 2 diabetes: a case study in a Chinese hospital. Asia Pac. J. Public Health 27(Suppl. 2), 49S–54S (2015).
6.
Hu H, Sawhney M, Shi L et al. A systematic review of the direct economic burden of Type 2 diabetes in china. Diabetes Ther. 6(1), 7–16 (2015).
7.
Dakin HA, Devlin NJ, Odeyemi IA. ‘Yes’, ‘No’ or ‘Yes’, but multinomial modeling of NICE decision-making. Health Policy 77(3), 352–367 (2006).
8.
Palmer AJ, Clarke P, Gray A et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health 16(4), 670–685 (2013).
• Systematic comparison and validation exercises, to identify important differences between models, address key methodological challenges and discuss avenues of research to improve future diabetes models.
9.
Becker C, Langer A, Leidl R. The quality of three decision-analytic diabetes models: a systematic health economic assessment. Expert Rev. Pharmacoecon. Outcomes Res. 11(6), 751–762 (2011).
10.
Kong AP, Xu G, Brown N, So WY, Ma RC, Chan JC. Diabetes and its comorbidities – where East meets West. Nat. Rev. Endocrinol. 9(9), 537–547 (2013).
• Discusses how rapid changes in technology and human behavior have brought on the global epidemic of metabolic diseases and suggests that solutions will be based on using system change, technology and behavioural strategies to combat this societal-turned medical problem.
11.
CDC Diabetes Cost-effectiveness Group. Cost–effectiveness of intensive glycemic control, intensified hypertension control and serum cholesterol level reduction for Type 2 diabetes. JAMA 287(19), 2542–2551 (2002).
12.
Zhou H, Isaman DJ, Messinger S et al. A computer simulation model of diabetes progression, quality of life and cost. Diabetes Care 28(12), 2856–2863 (2005).
13.
Palmer AJ, Roze S, Valentine WJ et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost–effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr. Med. Res. Opin. 20(Suppl. 1), S5–S26 (2004).
14.
Lundqvist A, Steen CK, Johansen P, Andersson E, Willis M. Validation of the IHE Cohort Model of Type 2 Diabetes and the impact of choice of macrovascular risk equations. PloS ONE 9(10), e110235 (2014).
15.
Eddy DM, Hollingworth W, Caro JJ et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med. Decis. Mak. 32(5), 733–743 (2012).
• Describes recommendations for achieving transparency and validation, developed by a task force.
16.
Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and validation of risk equations for complications of Type 2 diabetes (RECODe) using individual participant data from randomized trials. Lancet Diabetes Endocrinol. 5(10), 788–798 (2017).
• Developed and validated the risk equations for complications of Type 2 diabetes.
17.
Yang W, Lu J, Weng J et al. Prevalence of diabetes among men and women in China. N. Engl. J. Med. 362(12), 1090–1101 (2010).
18.
Bragg F, Holmes MV, Iona A et al. Association between diabetes and cause-specific mortality in rural and urban areas of China. JAMA 317(3), 280–289 (2017).
19.
Sun GZ, Guo L, Wang XZ et al. Prevalence of atrial fibrillation and its risk factors in rural China: a cross-sectional study. Int. J. Cardiol. 182, 13–17 (2015).
20.
Zhao S, Zhao H, Wang X et al. A prospective study investigating the causes of warfarin underutilization in Chinese patients. Int. J. Clin. Pharm. 38(5), 1286–1293 (2016).
21.
Ding L, Xu Y, Wang L et al. The cardiometabolic risk profile of Chinese adults with diabetes: a nationwide cross-sectional survey. J. Diabetes Complications 31(1), 43–52 (2017).
22.
Jia WP, Xiang KS, Chen L, Lu JX, Wu YM. Epidemiological study on obesity and its comorbidities in urban Chinese older than 20 years of age in Shanghai, China. Obes. Rev. 3(3), 157–165 (2002).
23.
Xu B, Sun J, Deng X et al. Low serum magnesium level is associated with microalbuminuria in Chinese diabetic patients. Int. J. Endocrinol. 2013, 580685(2013).
24.
Huo X, Gao L, Guo L et al. Risk of nonfatal cardiovascular diseases in early onset versus late-onset Type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol. 4(2), 115–124 (2016).
25.
Wan E, Fong D, Fung C et al. Prediction of new onset of end stage renal disease in Chinese patients with Type 2 diabetes mellitus: a population-based retrospective cohort study. BMC Nephrol. 18(1), 257 (2017).
26.
Chinese Society of Endocrinology. Expert consensus on the prevention and treatment of Chinese Type 2 diabetes with dyslipidemia (2017 revised version). Chinese J. Endocrinol. Metab. 33(11), 925–936 (2017).
27.
Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360(9326), 7–22 (2002).
28.
Task Group of the Chinese Guidelines for pharmacoeconomic evaluations. China guidelines for pharmacoeconomic evaluations. China J. Pharmaceut. Econ. 6(3), 7–48 (2011).
29.
Gerstein HC, Miller ME, Genuth S et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 364(9), 818–828 (2011).
30.
Wing RR, Bolin P, Brancati FL et al. Cardiovascular effects of intensive lifestyle intervention in Type 2 diabetes. N. Engl. J. Med. 369(2), 145–154 (2013).
31.
Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the diabetes prevention program outcomes study. Lancet 379(9833), 2243–2251 (2012).
32.
Stehouwer C. New risk equations for complications of Type 2 diabetes are welcome, but a broader perspective is needed. Lancet Diabetes Endocrinol. 5(10), 759–761 (2017).
33.
Shi Z, Zhen S, Zimmet PZ et al. Association of impaired fasting glucose, diabetes and dietary patterns with mortality: a 10-year follow-up cohort in eastern China. ACTA Diabetol. 53(5), 799–806 (2016).
34.
Yang X, Ma RC, So WY et al. Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 diabetes mellitus. Cardiovasc. Diabetol. 7, 9 (2008).
35.
Liu JJ, Lim SC, Yeoh LY et al. Ethnic disparities in risk of cardiovascular disease, end-stage renal disease and all-cause mortality: a prospective study among Asian people with Type 2 diabetes. Diabet Med. 33(3), 332–339 (2016).
36.
Wong CK, Wong WC, Wan YF et al. Patient empowerment programme in primary care reduced all-cause mortality and cardiovascular diseases in patients with Type 2 diabetes mellitus: a population-based propensity-matched cohort study. Diabetes Obes. Metab. 17(2), 128–135 (2015).
37.
Wan EY, Fong DY, Fung CS, Lam CL. Incidence and predictors for cardiovascular disease in Chinese patients with Type 2 diabetes mellitus: a population-based retrospective cohort study. J. Diabetes Complications 30(3), 444–450 (2016).
38.
Janssen KJ, Moons KG, Kalkman CJ, Grobbee DE, Vergouwe Y. Updating methods improved the performance of a clinical prediction model in new patients. J. Clin. Epidemiol. 61(1), 76–86 (2008).
•• Reported the methods that can be applied to adjust the model, rather than to develop a new model.
39.
McEwan P, Bennett H, Qin L, Bergenheim K, Gordon J, Evans M. An alternative approach to modeling HbA1c trajectories in patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. 19(5), 628–634 (2017).
40.
Xue B, Head J, McMunn A. The associations between retirement and cardiovascular disease risk factors in China: a 20-year prospective study. Am. J. Epidemiol. 185(8), 688–696 (2017).
41.
Tielemans S, Geleijnse JM, Laughlin GA, Boshuizen HC, Barrett-Connor E, Kromhout D. Blood pressure trajectories in relation to cardiovascular mortality: the Rancho–Bernardo Study. J. Hum. Hypertens. 31(8), 515–519 (2017).
42.
Abbott RD, Sharp DS, Burchfiel CM et al. Cross-sectional and longitudinal changes in total and high-density lipoprotein cholesterol levels over a 20-year period in elderly men: the Honolulu heart program. Ann. Epidemiol. 7(6), 417–424 (1997).
43.
Loh TP, Ma S, Heng D, Khoo CM. Age-Related Changes in the cardiometabolic profiles in Singapore resident adult population: findings from the National Health Survey 2010. Plos ONE 11(8), e162102 (2016).
44.
Knopp RH, D'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with Type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease End Points in noninsulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29(7), 1478–1485 (2006).
45.
Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med. 360(2), 129–139 (2009).
46.
Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358(24), 2545–2559 (2008).
47.
Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N. Engl. J. Med. 355(23), 2427–2443 (2006).
48.
Wing RR, Bolin P, Brancati FL et al. Cardiovascular effects of intensive lifestyle intervention in Type 2 diabetes. N. Engl. J. Med. 369(2), 145–154 (2013).
49.
Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435), 685–696 (2004).
50.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131), 837–853 (1998).
51.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359(15), 1577–1589 (2008).
52.
Woodward M, Patel A, Zoungas S et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world: Results from the ADVANCE trial. Diabetes Care 34(12), 2491–2495 (2011).
53.
Chen J, Alemao E, Yin D, Cook J. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes Obes. Metab. 10(Suppl. 1), 33–42 (2008).
54.
Wan E, Fung C, Jiao FF et al. Five-year effectiveness of the multidisciplinary risk assessment and management program for primary care patients with Type 2 diabetes mellitus (RAMP-DM) on DM-related complications and health service use: a population-based and propensity-matched cohort study. Diabetes Care 41(1), 49–59 (2018).
55.
Jiao F, Fung CS, Wan YF et al. Effectiveness of the multidisciplinary risk assessment and management program for patients with diabetes mellitus (RAMP-DM) for diabetic microvascular complications: a population-based cohort study. Diabetes Metab. 42(6), 424–432 (2016).
56.
Sasaki A, Uehara M, Horiuchi N, Hasegawa K, Shimizu T A 15-year follow-up study of patients with noninsulin-dependent diabetes mellitus (NIDDM) in Osaka, Japan: factors predictive of the prognosis of diabetic patients. Diabetes Res. Clin. Pract. 36(1), 41–47 (1997).
57.
Ueshima K, Itoh H, Kanazawa N et al. Rationale and design of the standard versus intensive statin therapy for hypercholesterolemic patients with diabetic retinopathy (EMPATHY) study: a randomized controlled trial. J. Atheroscler. Thromb. 23(8), 976–990 (2016).
58.
Sone H, Tanaka S, Iimuro S et al. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with Type 2 diabetes: a nationwide multicentre randomized controlled trial (the Japan Diabetes Complications Study). Diabetologia 53(3), 419–428 (2010).
59.
Araki A, Iimuro S, Sakurai T et al. Long-term multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial–study design, baseline characteristics and effects of intervention. Geriatr. Gerontol. Int. 12(Suppl. 1), 7–17 (2012).
60.
Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1575–1585 (2010).
61.
McEwan P, Ward T, Bennett H, Bergenheim K. Validation of the UKPDS 82 risk equations within the Cardiff diabetes model. Cost Eff. Resour. Alloc. 13, 12 (2015).
62.
McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. Value Health 17(6), 714–724 (2014).
63.
Willis M, Johansen P, Nilsson A, Asseburg C. Validation of the economic and health outcomes model of Type 2 diabetes mellitus (ECHO-T2DM). Pharmacoeconomics 35(3), 375–396 (2017).
64.
Tanaka S, Tanaka S, Iimuro S et al. Predicting macro- and microvascular complications in Type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care 36(5), 1193–1199 (2013).
65.
Yang X, So WY, Kong AP et al. Development and validation of a total coronary heart disease risk score in Type 2 diabetes mellitus. Am. J. Cardiol. 101(5), 596–601 (2008).
66.
Charokopou M, Sabater FJ, Townsend R, Roudaut M, McEwan P, Verheggen BG. Methods applied in cost–effectiveness models for treatment strategies in Type 2 diabetes mellitus and their use in health technology assessments: a systematic review of the literature from 2008 to 2013. Curr. Med. Res. Opin. 32(2), 207–218 (2016).
67.
Yi Y, Philips Z, Bergman G, Burslem K. Economic models in Type 2 diabetes. Curr. Med. Res. Opin. 26(9), 2105–2118 (2010).
68.
Areosa SA, Vernooij RW, Gonzalez-Colaco HM, Martinez G. Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst. Rev. 6, D3804 (2017).
69.
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5(1), 64–74 (2006).
70.
Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7(3), e33411 (2012).
71.
Cai X, Hu D, Pan C et al. I ndependent predictors of cardiovascular disease (CVD) events identified in a cohort of Type 2 diabetes (T2D) patients in China. Diabetes 641, A387 (2015).
Information & Authors
Information
Published In
Pages: 749 - 763
PubMed: 30132342
Copyright
© 2018 Future Medicine Ltd.
History
Received: 2 January 2018
Accepted: 19 April 2018
Published online: 22 August 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Development and validation of a Health Policy Model of Type 2 diabetes in Chinese setting. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0001
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Kristoffer Nilsson, Adam Fridhammar, Riku Ota, Morten Sall Jensen, Michael Willis, Sofie Persson, Validation of the IHE type 2 diabetes cohort model in the Japanese clinical setting, Journal of Medical Economics, 10.1080/13696998.2025.2517506, 28, 1, (944-963), (2025).
- Eric S.H. Lau, Andrea O.Y. Luk, Lee-Ling Lim, Hongjiang Wu, Aimin Yang, Alice P.S. Kong, Ronald C.W. Ma, Risa Ozaki, Elaine Y.K. Chow, Chiu-Chi Tsang, Chun-Kwun O, Amy Fu, Edward W. Gregg, Philip Clarke, Wing-Yee So, Juliana N.M. Lui, Juliana C.N. Chan, Development and Validation of the Patient-Level Chinese Diabetes Outcome Model on Long-term Complications in Type 2 Diabetes: An Application of the Hong Kong Diabetes Register, Diabetes Care, 10.2337/dca24-0069, 48, 4, (579-587), (2025).
- Mari Pesonen, Virpi Jylhä, Eila Kankaanpää, Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review, JBI Evidence Synthesis, 10.11124/JBIES-23-00511, 22, 11, (2194-2266), (2024).
- Zixuan He, Xianqin Huang, Dingyi Chen, Guoan Wang, Yuezhen Zhu, Huangqianyu Li, Sheng Han, Luwen Shi, Xiaodong Guan, Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review, BMJ Global Health, 10.1136/bmjgh-2023-012780, 8, 11, (e012780), (2023).
- Marina Antoniou, Céu Mateus, Bruce Hollingsworth, Andrew Titman, A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus, PharmacoEconomics, 10.1007/s40273-023-01312-4, 42, 1, (19-40), (2023).
- Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, Lars Holger Ehlers, A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus, PharmacoEconomics, 10.1007/s40273-023-01268-5, 41, 11, (1469-1514), (2023).
- Xinyu Li, Fang Li, Junfeng Wang, Anoukh van Giessen, Talitha L. Feenstra, Prediction of complications in health economic models of type 2 diabetes: a review of methods used, Acta Diabetologica, 10.1007/s00592-023-02045-8, 60, 7, (861-879), (2023).
- Elton Mukonda, Susan Cleary, Maia Lesosky, A review of simulation models for the long-term management of type 2 diabetes in low-and-middle income countries, BMC Health Services Research, 10.1186/s12913-021-07324-0, 21, 1, (2021).
- Wen-Qiang Lin, Zhong-jie Cai, Tingting Chen, Mao-Bai Liu, Na Li, Bin Zheng, Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China, Frontiers in Endocrinology, 10.3389/fendo.2021.684960, 12, (2021).
- Jiayu Li, Yun Bao, Xuedi Chen, Limin Tian, Decision models in type 2 diabetes mellitus: A systematic review, Acta Diabetologica, 10.1007/s00592-021-01742-6, 58, 11, (1451-1469), (2021).